Considering these initial reports supporting possible roles of Tau in cancer, we report herein the outcome of a set of pan-cancer analyses aimed at demonstrating the relevance of Tau in malignancies, identifying the genes and pathways associated with Tau, quantifying the impact of Tau expression on the clinical outcome and drug response, and exploring the possible interplay with P53. This evidence concerns the gene TP53 and cancer.